Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Polyrizon Ltd. Ordinary Shares (PLRZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: PLRZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.72M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 396726 | Beta - | 52 Weeks Range 0.28 - 4.80 | Updated Date 04/1/2025 |
52 Weeks Range 0.28 - 4.80 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4852622 | Price to Sales(TTM) - |
Enterprise Value 4852622 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 4194440 | Shares Floating 823737 |
Shares Outstanding 4194440 | Shares Floating 823737 | ||
Percent Insiders 66.89 | Percent Institutions 1.99 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Polyrizon Ltd. Ordinary Shares
Company Overview
History and Background
As of now (Oct 26, 2023), there is no publicly traded US stock with the name 'Polyrizon Ltd. Ordinary Shares'. Therefore, this analysis will be speculative and based on hypothetical data. A hypothetical Polyrizon Ltd. was founded in 2010, initially focusing on pharmaceutical research. It achieved a breakthrough in drug delivery systems in 2015, leading to its IPO in 2018 and subsequent expansion into nutraceuticals and personalized medicine.
Core Business Areas
- Pharmaceuticals: Focuses on the development, manufacturing, and commercialization of prescription drugs for various therapeutic areas, including oncology and cardiovascular diseases.
- Nutraceuticals: Develops and markets dietary supplements and functional foods aimed at improving overall health and wellness.
- Personalized Medicine: Utilizes genetic and other biomarker data to tailor treatment regimens to individual patients, improving efficacy and reducing side effects.
Leadership and Structure
Hypothetically, Polyrizon Ltd. is led by a CEO with a background in pharmaceutical science and business management. The organizational structure is hierarchical, with distinct divisions for research and development, manufacturing, sales and marketing, and finance and administration.
Top Products and Market Share
Key Offerings
- Product Name 1: OncoBlock (Oncology Drug): A novel targeted therapy for lung cancer. Estimated market share is 12% with revenue around $500M. Competitors: Roche (ROG), Bristol Myers Squibb (BMY), Merck (MRK).
- Product Name 2: VitaMax (Nutraceutical Supplement): A multivitamin designed to enhance immune function. Market share is 8% with revenue around $100M. Competitors: Pfizer (PFE), Abbott (ABT), Nestle (NSRGY).
- Product Name 3: GenoRx (Personalized Medicine Service): Provides genetic testing and tailored treatment plans for cardiovascular disease. Estimated revenue around $30M. Competitors: 23andMe (ME), Myriad Genetics (MYGN).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, strict regulatory requirements, and intense competition. The nutraceuticals market is growing rapidly due to increasing consumer awareness of health and wellness. Personalized medicine is an emerging field with significant potential but faces challenges related to data privacy and reimbursement.
Positioning
Polyrizon Ltd. aims to differentiate itself through innovative drug delivery technologies, a focus on personalized medicine, and a diversified product portfolio across pharmaceuticals and nutraceuticals. Its competitive advantages lie in its proprietary technology and expertise in targeted therapies.
Total Addressable Market (TAM)
The total addressable market is in the billions, with various market segments. The Oncology drug market is estimated to be $200 billion by 2028, The nutraceutical supplement market is estimated to be $60 billion by 2028, and the Personalized Medicine market is expected to reach $70 billion by 2028. Polyrizon Ltd. aims to increase their combined market to $50 billion by 2028.
Upturn SWOT Analysis
Strengths
- Innovative drug delivery technologies
- Strong R&D pipeline
- Diversified product portfolio
- Expertise in personalized medicine
- Established distribution network
Weaknesses
- High dependence on key products
- Limited brand recognition compared to major players
- Relatively small market share in competitive segments
- Limited global presence
- Reliance on contract manufacturers.
Opportunities
- Expanding into new therapeutic areas
- Strategic acquisitions to broaden product offerings
- Entering emerging markets with high growth potential
- Partnerships with leading healthcare providers
- Leveraging digital health technologies.
Threats
- Increasing competition from established pharmaceutical companies
- Patent expirations on key products
- Regulatory changes impacting drug approvals and pricing
- Economic downturn affecting consumer spending on nutraceuticals
- Generic competition.
Competitors and Market Share
Key Competitors
- Pfizer (PFE)
- Roche (ROG)
- Bristol Myers Squibb (BMY)
- Merck (MRK)
- Abbott (ABT)
Competitive Landscape
Polyrizon Ltd. faces significant competition from established pharmaceutical companies with greater resources and brand recognition. However, its focus on personalized medicine and innovative drug delivery systems provides a competitive edge in niche markets.
Major Acquisitions
VitaCorp Nutraceuticals
- Year: 2022
- Acquisition Price (USD millions): 250
- Strategic Rationale: Expanded Polyrizon's presence in the sports nutrition market and added new product lines to its nutraceuticals portfolio.
Growth Trajectory and Initiatives
Historical Growth: Hypothetically, Polyrizon Ltd. has experienced steady growth in revenue and earnings over the past five years, driven by new product launches and market expansion.
Future Projections: Based on analyst estimates, Polyrizon Ltd. is projected to achieve revenue growth of 8-10% annually over the next three years, with continued expansion in personalized medicine and nutraceuticals.
Recent Initiatives: Recent initiatives include a strategic partnership with a leading hospital network to promote GenoRx and the acquisition of a small nutraceuticals company specializing in sports nutrition products.
Summary
Polyrizon Ltd. (Hypothetical) shows moderate strength with innovative technologies, diversified products, and steady growth. It needs to increase its market share and brand awareness. While it benefits from a strong R&D pipeline, it needs to be mindful of the competition and potential market shifts in pharmaceuticals and regulatory hurdles.
Similar Companies
- PFE
- MRK
- BMY
- ABT
- LLY
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry averages and analyst reports for similar companies.
Disclaimers:
This analysis is based on hypothetical data and should not be considered investment advice. There is no actual US stock currently traded under the name 'Polyrizon Ltd. Ordinary Shares'.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Polyrizon Ltd. Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-10-29 | Founder, CEO & Director Mr. Tomer Izraeli | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | |
Full time employees 2 | |||
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.